Loading...

Home
ETF
CGTX

CGTX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CGTX News

CGTX Shares Plunge 33% Amid Regulatory Concerns

Jun 24 2026stocktwits

Cognition Therapeutics Achieves Key FDA Alignment for Zervimesine Study

Jun 24 2026NASDAQ.COM

Cognition Therapeutics Aligns with FDA on Key Trial Aspects for Dementia Drug

Jun 24 2026seekingalpha

Cognition Therapeutics Receives FDA Feedback for DLB Psychosis Clinical Trial Plans

Jun 24 2026Newsfilter

Cognition Therapeutics Receives Patent Allowance for Zervimesine

Jun 16 2026Newsfilter

Cognition Therapeutics CEO to Present at Financial Conferences

Jun 01 2026Newsfilter

Cognition Therapeutics Discusses Positive Path Forward with FDA for Zervimesine Registration

May 21 2026Newsfilter

Cognition Therapeutics Secures New Donation to Extend EAP for DLB Patients

May 14 2026Newsfilter

Cognition Therapeutics Q1 Earnings Beat Expectations

May 07 2026seekingalpha

Cognition Therapeutics CEO to Present at Needham Conference

Apr 07 2026Newsfilter

Cognition Therapeutics Advances CT1812 to Late-Stage Trials for DLB Psychosis

Mar 31 2026Newsfilter

Cognition Therapeutics Reports Better-Than-Expected FY GAAP EPS

Mar 26 2026seekingalpha

Cognition Therapeutics Advances Zervimesine Clinical Development for DLB Psychosis

Mar 26 2026Newsfilter

COGNITION THERAPEUTICS INC: FDA PSYCHIATRY DIVISION MEETING ANTICIPATED BY MID-2026

Mar 26 2026moomoo

Cognition Therapeutics Reports FY Operating Loss of USD 47.799 Million

Mar 26 2026moomoo

Cognition Advances Zervimesine Development for DLB Psychosis Treatment

Mar 02 2026Newsfilter